.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,226,931

« Back to Dashboard

Claims for Patent: 9,226,931

Title:Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Inventor(s): Ahluwalia; Gurpreet (Orange, CA), Beddingfield; Frederick C. (Pacific Palisades, CA), Edwards; Sydney G. (Aliso Viejo, CA), Whitcup; Scott M. (Laguna Hills, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:14/199,402
Patent Claims: 1. A method of increasing hair growth in chemotherapy patients, the method comprising applying bimatoprost to one selected from the group consisting of eyelids, eyebrows and the scalp before, during, or after chemotherapeutic treatment.

2. The method of claim 1, wherein bimatoprost is 0.03% w/v bimatoprost and is applied at least once a day to the eyelids.

3. The method of claim 2, wherein the method results in eyelashes which are longer, thicker or darker compared to patients receiving no treatment.

4. The method of claim 2, wherein the method is applied for at least 6 months after completing chemotherapeutic treatment.

5. The method of claim 4, wherein the method is applied for at least 12 months after completing chemotherapeutic treatment.

6. The method of claim 3, wherein the number of eyelashes increases in comparison to post-chemotherapeutic patients who received no treatment.

7. The method of claim 1, wherein the bimatoprost is added during and after post-chemotherapeutic treatment.

8. The method of claim 2, wherein the method is applied twice a day.

9. The method of claim 8, wherein the bimatoprost is applied to the upper and lower eyelid margin of each eye.

10. The method of claim 1, wherein the method effectively treats post-chemotherapeutic hair loss.

11. The method of claim 1, further comprising the step of administering one selected from the group consisting of minoxidil and Propecia.RTM..

12. A method of preventing loss of eyelashes in patients undergoing a chemotherapeutic treatment, the method comprising applying bimatoprost to the eyelids before, during, or after chemotherapeutic treatment.

13. The method of claim 12, wherein bimatoprost is 0.03% w/v bimatoprost and the 0.03% w/v bimatoprost is applied at least once a day.

14. The method of claim 12, wherein the method results in less eyelash loss compared to patients receiving no treatment.

15. The method of claim 14, wherein the method is applied for at least 6 months after completing chemotherapeutic treatment.

16. The method of claim 14, wherein the method is applied for at least 12 months after completing chemotherapeutic treatment.

17. The method of claim 12, wherein the method is applied prior to receiving chemotherapeutic treatment.

18. The method of claim 17, wherein the method is applied for three months prior to receiving chemotherapeutic treatment.

19. The method of claim 12 wherein the bimatoprost is in the form of a solution or an emulsion.

20. The method of claim 12 wherein the bimatoprost is applied to the upper eyelid, the lower eyelid or both the upper and lower eyelid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc